Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Pharmaceutical & Biotechnology Outlook 2014: Japan Pharma


News provided by

Bharat Book Bureau

11 Feb, 2014, 15:30 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox

MUMBAI, India, February 11, 2014 /PRNewswire/ --

Bharat Book Bureau presents Global Pharmaceutical & Biotechnology Outlook 2014: Japan Pharma. 2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations. We find these regulations to be 'decisive' in spurring generic penetration significantly, with the main beneficiary being the Japanese government (or society) and not the generic companies. (http://www.bharatbook.com/biotechnology-market-research-reports/global-pharmaceutical-biotechnology-outlook-2014-japan-pharma.html)

     (Logo: http://photos.prnewswire.com/prnh/20130128/590935 )

The implications of new price-reversions are going to have many facets and will change conventional business models.  We expect many support services industries - CMOs, CROs and other allied services industries to benefit from these structural changes, while API importers will suffer.  We also expect consolidation and M&A activities to spur in Japan.

Innovation Takes the Driver's Seat:  While the new regulations will change the current business philosophy of doing business in patent expired space (>45% to total Japan market), the policy makers also discourage 'me too' innovations at the same time. The regulators however tend to support the 'first time in the world' level innovations by providing 'innovation premiums'.  Japanese innovators will now become more serious and selective in their R&D approach.  Previous year the Japanese innovators have focused on acquiring assets in - autoimmune, orphan diseases and oncology fields (Annexure 5).  We expect this trend to prevail in the coming years.  We find some of the candidates to remain in the limelight in 2014 along with some new additions - Edoxaban (Daiichi Sankyo), Invokana (Mitsubishi Tanabe), Dolutegravir (Shionogi), BBI-608 (Dainippon Sumitomo), Vedolizumab (Takeda), Xtandi (Astellas), Nivolumab (Ono) to hand-pick a few of them. The reports explain detail analysis on these key candidates.

The 138 pages report contains the detailed discussion of Japan biopharmaceutical market - which includes- Our view on the impact of 2014 price cuts on generic companies and innovator companies and detailed discussion on key attributes (consolidation activities, potential of R & D pipeline candidates, generic threat in domestic Japan market etc…) of leading Japanese innovator companies- Astellas, Chugai, Daiichi Sankyo, Dainippon Sumitomo,  Eisai, Kyorin, Kyowa hakko Kirin, Mitsubishi Tanabe, Shionogi,  Takeda and  leading Japanese generic companies- Nippon Chemiphar, Sawai and Towa.

Request for sample pages:  http://www.bharatbook.com/RequestSample.asp?pid=364878

Table of Contents

  • INNOVATORS:
  • New Price-Cuts - A Double Punch To The Innovators!
  • Table 1- New Slabs For Nhi Price Cuts For Long-listed Drugs
  • Table 2 - Expense Vs. Portability Of Japanese Innovators
  • Another Blow For Innovators In Not Institutionalizing The 'Innovation Premium'
  • GENERICS:
  • Pressure To Generic Discount Further Increased
  • Upcoming New Generics
  • Existing Generics
  • Table 3 - New Drug Prices For Existing Ge Drugs
  • Listing Of GE Drugs by Both GE Name And Brand To Promote Discounting
  • IMPLICATIONS:
  • Finding New Avenues Of Cost Saving Are Inevitable For GE Cos
  • Innovators Need To Redone Long-Listed Products Strategies
  • Consolidation Activities To Will Witness A Boost
  • Table 4 - Other REGULATION UNDER APRIL-14 REFORMS*
  • Table 5 -Portably Structure Of Select Generic Companies
  • Annexure 1 JAPAN GEnerics Market Model
  • Annexure 2 Japanese Innovators: Long Listed Exposure
  • Annexure 3 PATENT EXPIRY THROUGH 2016
  • JAPAN INNOVATORS
  • ASTELLAS: Successful Global Launch of Xtandi And Myrbetriq To Overcome Domestic worries!
  • Prograf Generics Launch in Japan
  • Xtandi
  • JP Approval ahead than Zytiga
  • What to watch out for in Detailed PREVAIL data in Late Feb at ASCO GU-14?
  • Prevail top line data of Xtandi - rPFS advantage and ease of use compensate absolute OS disappointment for urologist
  • Recent US prescription trends of Xtandi are encouraging
  • Isavuconazole: Isavuconazole QIDP designation and our expectation
  • Competitive landscape of Antifungals

For more information and complete table of contents:  http://www.bharatbook.com/biotechnology-market-research-reports/global-pharmaceutical-biotechnology-outlook-2014-japan-pharma.html

Related Reports:

  • Global Pharmaceutical & Biotechnology Outlook 2014: Rising Stars
  • Global Radiopharmaceuticals Market Insight
  • Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech
  • PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
  • Global Pharmaceutical & Biotechnology Outlook 2014: Global Pharma
  • Global Pharmaceutical & Biotechnology Outlook 2014: India Pharma

Related Category:

  • Biotechnology
  • Biopharmaceutical
  • Pharma industry
  • Pharmaceutical
  • Healthcare

About Bharat Book Bureau

Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.

Contact us:
Poonam
Bharat Book Bureau
USA/Canada - 1-866-279-8368 (Toll free)
India: +91-22-27810772, 27810773
Blog: http://blog.bharatbook.com
E: poonam@bharatbook.com
W: http://www.bharatbook.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.